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Atherosclerosis is a progressive insidious chronic disease that underlies most of
the cardiovascular pathologies, including myocardial infarction and ischemic stroke.
The malfunctioning of the lysosomal compartment has a central role in the etiology
and pathogenesis of atherosclerosis. Lysosomes are the degradative organelles of
mammalian cells and process endogenous and exogenous substrates in a very efficient
manner. Dysfunction of these organelles and consequent inefficient degradation of
modified low-density lipoproteins (LDL) and apoptotic cells in atherosclerotic lesions
have, therefore, numerous deleterious consequences for cellular homeostasis and
disease progression. Lysosome dysfunction has been mostly studied in the context
of the inherited lysosomal storage disorders (LSDs). However, over the last years
it has become increasingly evident that the consequences of this phenomenon
are more far-reaching, also influencing the progression of multiple acquired human
pathologies, such as neurodegenerative diseases, cancer, and cardiovascular diseases
(CVDs). During the formation of atherosclerotic plaques, the lysosomal compartment
of the various cells constituting the arterial wall is under severe stress, due to
the tremendous amounts of lipoproteins being processed by these cells. The
uncontrolled uptake of modified lipoproteins by arterial phagocytic cells, namely
macrophages and vascular smooth muscle cells (VSMCs), is the initial step that
triggers the pathogenic cascade culminating in the formation of atheroma. These
cells become pathogenic “foam cells,” which are characterized by dysfunctional
lipid-laden lysosomes. Here, we summarize the current knowledge regarding the
origin and impact of the malfunctioning of the lysosomal compartment in plaque
cells. We further analyze how the field of LSD research may contribute with some
insights to the study of CVDs, particularly how therapeutic approaches that target
the lysosomes in LSDs could be applied to hamper atherosclerosis progression and
associated mortality.
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Cardiovascular diseases (CVDs) are a group of disorders
affecting the function of the heart and blood vessels and
constitute the current leading cause of death worldwide,
claiming more lives than all forms of cancer combined (Virani
et al., 2020). Atherosclerosis is the main contributor to this
burden, being at the basis of various forms of CVD, including
peripheral arterial disease, myocardial infarction and stroke
(Mendis et al., 2011). The term atherosclerosis derives from
the Greek “athere” (gruel) and “skleros” (hard), referring to the
“waxy” plaques inside blood vessels described over 100 years
ago. This disease is known to develop silently over decades
without noticeable symptoms, until the patients experience
harmful complications. Risk factors for atherosclerosis
include hypertension, hypercholesterolemia, diabetes mellitus,
obesity, and smoking (Libby et al., 2019). The factors and
mechanisms that initiate atherogenesis are particularly
complex and still not completely understood. Uncovering
the molecular mechanisms driving plaque development in
arterial cells is of the uttermost importance for the future
development of more accurate disease biomarkers and more
effective therapies.
Major Steps of Plaque Development
Diffuse Intimal Thickening (DIT)
Atherosclerotic lesions are predominantly located in the
intima layer of middle-sized and large elastic and muscular
arteries, especially at branch points and in areas of high
vessel curvature (Lusis, 2000; Tabas and Bornfeldt, 2016;
Figure 1A). These areas are subjected to low shear stress
and disturbed flow, which modulate the expression and
structure of permeability-related intercellular junctional proteins
in endothelial cells (ECs) (Milutinović et al., 2020). As
a consequence, the endothelial barrier becomes permeable,
leading to the accumulation and sequestration of low-density
lipoproteins (LDLs) in the intima (Colin et al., 2014). In
response to pro-atherogenic stimuli, vascular smooth muscle
cells (VSMCs) start to proliferate and to produce a high
amount of modified extracellular matrix (ECM). This process
underlies the occurrence of diffuse intimal thickening (DIT),
also known as “fatty streak,” already present in human arteries
even before atherosclerosis develops (Nakashima et al., 2008;
Figure 1B).
Pathological Intimal Thickening (PIT)
In the early stages of atherosclerosis intima thickening becomes
pathological (PIT), as the ECM facilitates the binding, retention,
and deposition of further lipoprotein-derived lipids. The
LDLs are subsequently modified by numerous mechanisms
including oxidation and enzymatic cleavage, transforming
them into pro-inflammatory oxidized LDL (oxLDL). These
modified lipoproteins damage the endothelium, triggering
a pro-inflammatory cascade initiated by the activation of
ECs, which start secreting chemo-attractants [e.g., monocyte
chemotactic protein-1 (MCP-1)] (Cushing et al., 1990) and
adhesion molecules (e.g., ICAM-1, P-selectin, E-selectin,
PCAM-1, and VCAM-1) (Davies et al., 1993; Tabas et al.,
2007). The presence of these molecules causes local recruitment
of leukocytes (mainly monocytes) from the bloodstream,
which adhere and migrate into the vessel wall (Figure 1B).
In the intima, monocytes differentiate predominantly into
pro-inflammatory macrophages (Ross, 1999), which express
the scavenger receptors (SRs) and internalize modified
lipoproteins. The infiltration and proliferation of macrophages
is a characteristic feature of the progression of PIT to
fibroatheroma stage.
Fibroatheroma Stage
The pro-inflammatory plaque macrophages give rise to local
inflammation by secreting pro-inflammatory cytokines [e.g.,
tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and
IL-1β] (Figure 1D), which recruit T and B cells to the lesion
site (Zhou and Hansson, 1999). Akin to macrophages, VSMCs
are efficient phagocytic cells that take up modified and oxLDL
via SRs (as well as by micropinocytosis). As a consequence,
VSMCs differentiate into macrophage-like cells (Chellan et al.,
2018). This unrestrained uptake of oxLDL by macrophages and
macrophage-like cells eventually takes a toll on the lysosomal
compartment, responsible for the processing of the incoming
lipoproteins. The saturation of the degradative capacity of
lysosomes causes the accumulation of unprocessed lipids in these
organelles and in cytosolic lipid droplets (LDs). These lipid-
laden cells transform into the so-called foam cells, major players
in the ensuing steps of the atherogenic cascade (Allahverdian
et al., 2014; Vengrenyuk et al., 2015). Foam cells undergo
apoptosis and accumulate calcium in the acidic extracellular
space. Given that the now dysfunctional macrophages and
VSMCs are the main cell types responsible for the efferocytic
removal of dead cells and apoptotic bodies, a lipid-rich necrotic
core starts to form in fibroatheroma (Libby et al., 2019;
Figure 1D).
Plaque Rupture and Thrombosis
Initially, the necrotic core is surrounded by a thick fibrous
cap composed of VSMCs, which protects the vulnerable
plaque (Durham et al., 2018). However, the unresolved
inflammation leads to the production of cytokines that
induce apoptosis of VSMCs or differentiation into cells
with osteochondrogenic phenotype, which promote mineral
deposition in the atherosclerotic plaque (Ceneri et al., 2017;
Durham et al., 2018). Eventually, the continuous erosion of
the fibrous cap, due to VSMC death and the degradation of
collagen by metalloproteases, destabilizes atherosclerotic plaques.
The final trigger to this pathogenic cascade is the expansion
of the necrotic core due to intraplaque neovascularization and
the extravasation of platelets and erythrocytes (Milutinović
et al., 2020). The now thin-cap fibroatheroma is unstable and
prone to rupture and thrombosis. Thrombotic events can then
lead to myocardial infarction and stroke, with major clinical
consequences such as death and disability.
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FIGURE 1 | Lysosome (dys)funtion in the initial and final stages of plaque development. (A) Anatomically, large arteries consist of three well defined and
morphologically distinct layers. The intima, the innermost layer in direct contact with the blood stream, comprising an endothelial layer surrounded by a connective
tissue basement membrane with elastic fibers. The media is the thickest layer and consists primarily of VSMCs. The outermost adventitia, with connective tissue and
varying amounts of collagenous and elastic fibers, attaches the artery to the surrounding tissue. (B) In the initial stages of plaque development (fatty streak) LDL
infiltrates the intima, where it undergoes oxidation and other modifications. The formed oxLDL causes the proliferation of VSMCs and triggers the secretion of
adhesion molecules (1) and chemoattractants (2) by ECs, which in turn recruit monocytes from the blood stream. In the intima, monocytes differentiate into
macrophages that clear LDL and oxLDL. (C) In macrophages of the intima the LDL is taken up by the LDLR and routed to the lysosomes (Lys) where the acid lipase
LAL hydrolases the CE and TG to FC and fatty acids. The cathepsin (CTS) proteases breakdown the protein apoB. FC is exported from the lysosomes by NPC1 and
then directed to the different organelles (ER, PM, etc.). The ER enzyme ACAT esterifies cholesterol to CE, which are stored in cytosolic LDs. CE can be converted
back to FC by NCEH. Excess FC is effluxed via the ABCA1 plasma membrane (PM) transporter. Efferocytosis and selective autophagy converge to the lysosomal
compartment for degradation of substrates sequestered in phagosomes and autophagosomes, respectively. Intralysosomal hydrolysis dependents on the activity of
the proton (H+) pump v-ATPase that maintains the intraluminal acidic pH. Nutrients such as aminoacids (aa) and FC are sensed by the LYNUS machinery of which
mTORC1 is a part of. Abundance of nutrients dictates the inactivity of mTORC1 and the translocation of (14-3-3) free TFEB to the nucleus (Nu) to drive the
transcription of lysosome and autophagy genes. The uptake of LDL is regulated by the action of the SREBP transcription factors. (D) In advanced plaques
(fibroatheroma stage) a necrotic core is formed with lipid-laden foam cells and necrotic cells. Plaque rupture is prevented by the fibrous cap formed by VSMCs that
migrated from the intima. Foam cells secrete pro-inflammatory cytokines aggravating local inflammation (3). (E) As a result of the unregulated uptake of oxLDL by
SRs at the surface of foam cells, the lysosomal compartment becomes overloaded with partially digested oxLDL, FC and eventually CCs. The accumulation of these
materials causes lysosomal membrane permeability (LMP), the loss of the proton gradient and the release of CTS into the cytosol. There, these proteases participate
in the NRLP3 inflammasome activation cascade that culminates with the processing of pro-IL-1β into IL-1β by active caspase 1. The lysosomal iron (Fe2+) pool may
be one of the factors determining a decrease in the activity of the v-ATPase besides contributing to further LDL oxidation. The elevated lysosomal pH reduces the
activity of the hydrolases. The decreased lysosomal hydrolytic function causes an impairment in the efferocytic and autophagic capacity of the cell. The accumulation
of FC may be the culprit for the hyperactivation of mTORC1 which phosphorylates TFEB causing its retention (in a complex with 14-3-3) in the cytosol. This prevents
lysosome biogenesis. Exocytosis of lysosomal contents might contribute to atherogenesis through the release to the extracellular space of partially degraded
materials and the release of CTS, whose activity contributes to LDL aggregation and ECM breakdown. Some images in this figure were adapted with permission
from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License (http://smart.servier.com/).
Lysosomal Dysfunction in
Atherosclerosis
During plaque development, one organelle in particular endures
a sheer amount of stress. Lysosomes, the recycling centers of the
cell, must cope with the unrestrained amounts of lipoproteins
taken up by foam cells, process the mounting apoptotic bodies
engulfed by phagocytes and, as a nutrient sensing platform,
regulate the unbalanced cellular metabolic status and growth rate.
The giant task of these small organelles in atherosclerotic plaques
was first recognized by the pioneering work of Christian De Duve
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(Peters and de Duve, 1974; Shio et al., 1974), Nobel prize recipient
for the discovery of these acidic organelles (De Duve et al., 1955).
De Duve and his team were the first to describe that the arterial
cells of rabbits fed a cholesterol-rich diet progressively transform
into foam cells due to a dysfunctional lysosomal compartment,
unable to dispose of lipoproteins (Peters and de Duve, 1974;
Shio et al., 1974). Various posterior studies have confirmed these
ground-breaking observations (Goldfischer et al., 1975; Haley
et al., 1977; Fowler et al., 1980; Bobryshev et al., 2013). In
this review, we explore the most recent discoveries regarding
the molecular details commanding the lysosomal dysfunction
observed in plaque cells and the way in which this contributes




These small cytoplasmic organelles are spherical membrane-
bound vesicles containing numerous acidic hydrolytic enzymes
that can breakdown biological polymers, such as lipids, proteins,
carbohydrates, and nucleic acids (Ballabio and Bonifacino,
2020). Lysosomes degrade and recycle extracellular material
via endocytosis, macropinocytosis and phagocytosis, and
intracellular material via autophagy. The catalytic function
of lysosomes makes them indispensable for multiple cellular
processes, including antigen presentation, pathogen inactivation,
downregulation of surface receptors and turnover of cellular
components (Saftig and Puertollano, 2020). Importantly,
lysosomes not only recycle cellular building blocks, but
rather constitute a key signaling hub, able to sense and
integrate information about changing environmental conditions
and quickly translate it into cellular adaptation (Saftig and
Puertollano, 2020). The cellular metabolic and signaling status
is relayed via the microphthalmia family of transcription factors
(MiT/TFE) and determines the particular rate of lysosomal
biogenesis, autophagy and exocytosis (Marques and Saftig, 2019).
To this date, four members of the MiT/TFE family have
been identified: microphthalmia-associated transcription factor
(MITF), transcription factor EB (TFEB), TFE3, and TFEC
(Steingrímsson et al., 2004). All four members of the MiT/TFE
family have the ability to bind a unique enhancer box (E-
box) DNA motif [also referred to as CLEAR (coordinated
lysosomal expression and regulation)] within the proximal
promoters of lysosomal and autophagy genes (Sardiello et al.,
2009). TFEB is considered the master regulator of lysosome
biogenesis and therefore plays a central role in the control of
cell and organismal homeostasis (Sardiello et al., 2009; Settembre
et al., 2013; Napolitano and Ballabio, 2016). The subcellular
localization and activity of TFEB are regulated by the mechanistic
target of rapamycin (mTOR)-mediated phosphorylation, a kinase
present at the lysosomal surface (Napolitano and Ballabio, 2016).
Under nutrient−rich conditions, TFEB is phosphorylated by
the mTOR complex 1 (mTORC1) kinase and retained in the
cytoplasm bound to the 14-3-3 chaperone protein (Sancak
et al., 2010). Other growth-regulating kinases such as MAPK
kinase (MEK)/extracellular signal-regulated kinase (ERK) and
glycogen synthase kinase 3 (GSK3) can also promote TFEB
phosphorylation (Perera et al., 2019). In response to starvation
and lysosomal stress, TFEB is dephosphorylated by the calcium-
dependent phosphatase calcineurin, translocating to the nucleus
and inducing the transcription of target genes (Settembre et al.,
2011; Medina et al., 2015). Under oxidative stress conditions
TFEB and TFE3 can also be dephosphorylated by the action
of protein phosphatase 2A (PP2A), causing their nuclear
translocation (Martina and Puertollano, 2018). Defects that
impair any of the functions of lysosomes, cause the accumulation
of undigested or partially digested macromolecules in their
interior (that is, “storage”) or impair the transport of molecules,
which can result in cellular damage.
Lysosomal Storage Disorders
Lysosomes are comprised by more than 70 hydrolases, 200
membrane proteins and numerous other associated proteins
(Saftig and Puertollano, 2020). Of the ∼1,300 genes involved in
lysosomal function, approximately 70 monogenic disorders of
lysosomal catabolism have been described. These are classified
as Lysosomal Storage Diseases (LSDs), heritable (inborn) errors
of metabolism affecting the function of the lysosome, most of
which are inherited as autosomal recessive traits (Platt et al.,
2018). These disorders are individually rare, but collectively
affect 1 in 5,000 live births (Platt et al., 2018). LSDs typically
manifest in infancy and childhood, although adult-onset forms
also occur. Most LSDs have a progressive neurodegenerative
clinical course, yet symptoms in other organ systems are
frequent. Cardiac manifestations are a common finding in many
LSDs, underscoring the fundamental role of lysosomes in the
homeostasis of the cardiovascular system (Laney et al., 2018; Chi
et al., 2020).
Cardiovascular Pathology in LSDs
The most severe cardiovascular manifestations in LSDs have
prenatal onset, for example, cardiomyopathy in infantile-onset
Pompe disease (lysosomal acid alpha-glucosidase deficiency),
while other manifestations occur more subtly at later stages
and become more life-threatening over time, in conditions
such as Fabry disease (alpha-galactosidase A deficiency) (Laney
et al., 2018). In the adult variants of LSDs, cardiovascular
manifestations can be pathognomonic for the disease itself,
but often occur earlier than expected (Laney et al., 2018).
Patients suffering from an attenuated form of lysosomal acid
lipase (LAL) deficiency, also known as cholesterol ester storage
disease (CESD), provide a prototypical example. CESD patients
suffer from premature atherosclerosis and early onset CVD
due to unfavorable lipid profiles in adolescence that may be
aggravated by other risk factors such as elevated body mass
index (BMI) (Erwin, 2017). Cystinosis patients, with mutations
in the gene encoding for the lysosomal cysteine transporter
(CTNS), are also at high risk for the development of vascular
calcifications and obstructive atherosclerosis (Ueda et al., 2006).
Further highlighting the role of the autophagy-lysosomal system
in cardiovascular homeostasis, deficiency in the lysosome-
associated membrane protein 2 (LAMP2) (one of the main
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lysosomal membrane glycoproteins) causes Danon disease, a
pathology characterized by massive autophagosome deposition
in cardiomyocytes (Platt et al., 2018; Zhu et al., 2020). LAMP2
deficiency leads to autophagy impairment and autophagosome
aggregation in these cells, resulting in cardiac defects (Tanaka
et al., 2000). Even single defects in the lysosome machinery, such
as represented by monogenic LSDs, can thus have a significant
impact on the cardiovascular system.
Acquired LSDs
The concept of LSD has been broadened to encompass
acquired pathologies in which malfunction of the autophagy-
lysosomal system plays a significant etiological role (Marques
and Saftig, 2019). External and acquired factors, such as diet
or pathogen infection, can impact the function of lysosomes.
The term “acquired LSDs” has thus been coined to refer to
more common human pathologies presenting a malfunctioning
lysosomal compartment, including neurodegenerative diseases,
kidney and cardiovascular diseases, as well as other age-related
diseases. Christian de Duve himself defined foam cell formation
in atherosclerosis as a variant of LSD (Peters and de Duve, 1974;
Shio et al., 1974; Jerome, 2006). Therefore we will now turn our
attention to the molecular mechanisms that have attested to the
hypothesis since it was raised by De Duve almost 50 years ago.
THE ROLE OF LYSOSOMES IN FOAM
CELL FORMATION
Lysosomal LDL Processing
In early atherosclerotic lesions, monocyte-derived macrophages
take up the retained lipoproteins through receptor-mediated
endocytosis and fluid-phase pinocytosis (Figure 1C). Native LDL
are mainly recognized by the LDL receptor (LDLR), which is
responsible for the cellular endocytosis process (Brown and
Goldstein, 1986). The uptake of LDL particles is a highly
regulated system with regulatory feedback mechanisms through
suppression of the sterol-regulatory element-binding protein
(SREBP) pathway to avoid excessive uptake and lipid overload
(Brown and Goldstein, 1997; Figure 1C). The endocytosed LDL
are shuttled to lysosomes in order to be metabolized. During
that process, cholesteryl esters (CE) are hydrolyzed by the LAL
into free cholesterol (FC) and fatty acids (Ouimet et al., 2011;
Sergin and Razani, 2014). FC is rapidly exported out of the
lysosome by the joint action of the Niemann-Pick C1 and C2
(NPC1 and NPC2) proteins (Figure 1C). Membrane contact
sites mediate cholesterol delivery to other organelles, including
the endoplasmic reticulum (ER) and peroxisomes (Meng et al.,
2020). The excess of FC can be effluxed to the periphery through
ATP-binding cassette transporter A1 (ABCA1)-mediated efflux
to nascent high-density lipoproteins (HDL) (Brown et al., 1980;
Figure 1C). However, if the influx of LDL-derived cholesterol
is higher than the efflux, the excess of FC is re-esterified in
the ER by acyl-CoA:cholesteryl acyltransferase (ACAT) and
stored in the cytosol in LDs in the form of CE (Meiner et al.,
1996; Figure 1C). Cholesterol re-esterification is a regulated
and protective mechanism indispensable to prevent excessive FC
accumulation in membranes, mainly in the ER, which could be
toxic for the cell (Brown and Goldstein, 1983). Even though LD
accumulation eventually leads to foam cell formation (Brown
et al., 1980), this process is essentially reversible. When the rate
of cholesterol efflux is sufficient, the action of the cytoplasmic
enzyme neutral cholesterol-ester hydrolase (NCEH) can convert
CE back to FC for use by the cell (Figure 1C). Alternatively,
cells can generate FC through the autophagic uptake of LDs
with subsequent LAL-dependent degradation of CE, a form of
selective autophagy named lipophagy (Ouimet and Marcel, 2012).
This cycle of hydrolysis and re-esterification is continuous and
has a half-life of approximately 24 h (Gonen and Miller, 2020).
LDL Oxidation
The LDL and other apoB-containing particles accumulated in
the artery wall may undergo extracellular and intracellular
(lysosomal) modifications, which are associated with increased
atherogenicity. These cholesterol-containing structures may
be oxidized, aggregated, or enzymatically modified. These
modifications significantly affect the physicochemical and
biological properties of the lipoproteins (Aviram, 1993; Hoff
and Hoppe, 1995). One of the major chemical modifications
of LDL is oxidation, involving free radical mediated lipid
peroxidation, which was already demonstrated to occur in vivo
(Gibson et al., 2018; Domingues et al., 2021). The presence
of different subsets of lipases and oxygenases in the arterial
wall may result in the occurrence of numerous forms of
modified LDL in vivo. OxLDL is thus an umbrella term that
describes a vast mixture of over 3,000 molecules, most of which
with biological activity (Gibson et al., 2018). In the field of
atherosclerosis a debate persists regarding the exact mechanisms
by which LDLs are oxidized in the interior of arteries (see
“Lysosomal Iron Metabolism” section). Regardless of their origin,
these modifications decrease the ability of LDL to bind to the
LDLR (Avogaro et al., 1991). The pro-atherogenic potential
of oxLDL has been solidly established (Goldstein et al., 1979;
Steinberg et al., 1989; Jerome and Lewis, 1990; Aviram, 1993),
although the role of each particular bioactive molecule remains
largely unexplored. While most research has focused on the
atherogenicity of oxidized phospholipids and oxysterols, our
recent studies suggest that the end products of CE oxidation,
cholesteryl hemiesters, may be responsible for some of the pro-
atherogenic properties ascribed to oxLDL (Estronca et al., 2012;
Domingues et al., 2017, 2021).
OxLDL-Induced Lysosomal Dysfunction
As the lesion progresses, foam cells arise as the result of the
uncontrolled uptake and defective metabolization of modified-
LDL accumulated in the vessel wall by cells. The uptake
of modified lipids by phagocytes, namely macrophages and
VSMCs, is mediated by alternate SRs (Figure 1E). These
receptors include lectin-like receptors (LOX), SR-class A,
CD36, and toll-like receptors (TLR) (Hoff and Hoppe, 1995;
Kunjathoor et al., 2002; Bolick et al., 2009; Adamson and
Leitinger, 2011), and in contrast to LDLR their expression
is not down-regulated by increased intracellular cholesterol
levels (Miller et al., 2005; Mehta et al., 2007; Choi et al., 2009;
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Manning-Tobin et al., 2009). The lack of a negative feedback
regulation results in excessive intracellular storage of these
lipids (Röhrl and Stangl, 2018). Furthermore, the uptake of
oxLDL by SRs blocks the normal handling of cholesterol at
the endolysosomal stage (Figure 1E). Studies indicate that
only approximately 50% of oxLDL are effectively degraded in
lysosomes, in part due to their resistance to the proteolytic
activity of lysosomal proteases (Lougheed et al., 1991; Jessup et al.,
1992; Yancey and Jerome, 1998). Defective oxLDL hydrolysis
results in their trapping in the lysosomal compartment,
decreasing the exit of FC from the lysosomes to be esterified
by ACAT (Lougheed et al., 1991). In time this causes
lysosomal engorgement, due to further CE accumulation, and
ultimately cholesterol crystal (CC) formation (Sheedy et al., 2013;
Figure 1E). The progressive lysosomal dysfunction in plaque
foam cells constitutes a form of lipidosis, i.e., irreversible lipid
accumulation, a condition very similar to the one observed in
LSDs such as Wolman and Niemann-Pick type C (NPC) diseases
(Marques and Saftig, 2019).
LYSOSOMAL DYSFUNCTION IN FOAM
CELLS
A large number of open questions still surround the mechanisms
by which oxLDL triggers lysosomal lipidosis. Nonetheless,
considerable advances have been made in recent years concerning
the characterization of the multiple processes driving the
impairment of lysosomal homeostasis in atherosclerotic plaque
cells. Numerous studies have demonstrated that oxLDL, CC, and
other modified lipids are able to alkalize lysosomal pH, impair the
degradative capacity of lysosomal hydrolases and cause damage
to the lysosomal membrane (Cox et al., 2007; Jerome et al., 2008;
Sheedy et al., 2013; Emanuel et al., 2014).
Increased Lysosomal pH
Each cell contains different populations of lysosomes, which
can be distinguished by their position, size, acidification and
reformation properties (Bright et al., 2016). Hydrolysis of cargo
takes place in the perinuclear lysosomal population, characterized
by the acidic pH (4.5–5.0). The intralysosomal acidic pH is
the result of an electrochemical gradient maintained mostly
by the vacuolar type-ATPase (v-ATPase) (Figure 1C), aided
by the chloride channel CLC-7 (Mindell, 2012). One of the
first observations made in macrophages exposed to oxLDL, was
the inability of these cells to maintain an acidic lysosomal pH
(Cox et al., 2007; Emanuel et al., 2014). In these lipid-engorged
cells, the intralysosomal accumulation of FC directly inhibits the
activity of the v-ATPase at the lysosomal membrane (Cox et al.,
2007; Jerome et al., 2008). Another way by which oxLDL and the
accumulated CC may cause alkalization of the lysosomal pH is
through the induction of damage to the lysosomal membrane,
causing leakage of the intraluminal contents and consequent
loss of the proton gradient (Li et al., 1998a,b; Yuan et al., 2000;
Emanuel et al., 2014; Figure 1E). The increase in lysosomal pH
appears to be one of the prime insults affecting this organelle and
triggering the ensuing malfunction.
Impaired Degradative Capacity
All lysosomal hydrolases, responsible for the catabolism of
endogenous and exogenous substrates, have optimal activity
at acidic pH. The raise in lysosomal pH observed in foam
cells impairs the ability of these enzymes to break down the
incoming modified lipoproteins (Brown et al., 2000). This drop
in lysosomal hydrolytic capacity has been firmly established in
various atherosclerosis models (Jerome and Lewis, 1990; Yancey
and Jerome, 2001; Griffin et al., 2005). LAL is the primary enzyme
responsible for the hydrolysis of CE derived from lipoproteins.
Alkalization of lysosomal pH by oxLDL was shown to directly
impair LAL-mediated CE hydrolysis (Cox et al., 2007). Another
class of enzymes fundamental for the catabolism of lipoproteins
are cathepsin proteases, that catalyze the hydrolysis of apoB
proteins. Several studies have shown that loading of cells with
oxLDL increases the resistance of proteins to being degraded by
cathepsins, namely cathepsin D (the most abundant lysosomal
protease) and cathepsin B (Lougheed et al., 1991; Jessup et al.,
1992). The ability of lysosomal cathepsins to degrade apoB
appears to be directly inhibited by the phospholipids in oxLDL
(O’Neil et al., 2003), in the case of cathepsin D, or in the
case of cathepsin B by the covalent binding of the lipoproteins’
aldehydes to the cysteine and histidine residues on the enzyme’s
active site (Hoppe et al., 1994; O’Neil et al., 1997; Crabb, 2002).
This may, in turn, hamper the LAL-mediated hydrolysis of
the CE in the core of oxLDL (Dubland and Francis, 2015). In
accordance, histological studies of human atherosclerotic plaques
have demonstrated the presence of lysosomes loaded with
undegraded or partially degraded oxLDL (Mitchinson et al., 1985;
Figure 1E). This inability to process oxLDL can eventually lead to
the formation of toxic ceroid-lipofuscin aggregates in the foam
cells of atherosclerotic lesions (Mitchinson, 1982; Mitchinson
et al., 1985). The formation of these polymerized products of lipid
oxidation is known to occur with aging and neurodegenerative
disease, as well as in the neurological LSD neuronal ceroid
lipofuscinosis (NCL), as a consequence of impaired lysosomal
hydrolytic capacity (Seranova et al., 2017; Marques et al., 2019).
Lysosomal Membrane Damage
OxLDL and CC, formed as a consequence of lysosomal FC
accumulation, can cause damage to the lysosomal membrane. In
macrophages, oxLDL- and CC-mediated lysosomal membrane
permeabilization (LMP) causes loss of proton gradient and
a massive release of lysosomal hydrolases into the cell
cytosol (Figure 1E; Sheedy et al., 2013; Sergin et al., 2015).
Downstream consequences of lysosomal leakiness may include
NOD-like receptor family pyrin domain containing 3 (NLRP3)
inflammasome activation (see “Inflammation” section) and cell
death responses [for information on lysosomal-mediated cell
death pathways see Aits and Jäättelä (2013)]. The mechanisms
by which cells respond to LMP have only recently begun to
be elucidated. Limited damage to the lysosomal membrane
triggers the calcium-dependent recruitment of the ESCRT-III
machinery to the place of the rupture and prompt repair
(Skowyra et al., 2018). When the damage is too significant
and repair is no longer an option, lysosomal proteins are
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selectively ubiquitinated, marking the damaged organelles to
be sequestered by autophagosomes and eventually incorporated
into autolysosomes for degradation (Hung et al., 2013; Maejima
et al., 2013). This selective autophagic disposal of damaged
lysosomes was termed lysophagy. As we will discuss below (see
“Autophagy” section), autophagy is disturbed in atherosclerosis,
and the removal of damaged lysosomes may thus be impaired,
contributing to the aggravation of the pathogenic cascade.
THE IMPACT OF LYSOSOMAL
DYSFUNCTION IN ATHEROGENESIS
Lysosomes are indispensable players in several mechanisms
that affect atherosclerotic disease progression, including
inflammation, efferocytosis, exocytosis, autophagy, mTOR
signaling, and iron metabolism. The irreversible lipid
accumulation taking place in the lumen of lysosomes of advanced
plaque cells severely affects the ability of the autophagy-lysosomal
axis to perform these fundamental functions, further aggravating
the pathological cascade through, for example: iron-mediated
lysosomal oxidation of lipoproteins, exocytosis of partially
degraded oxLDL, inefficient disposal of apoptotic bodies and
inflammasome activation. Next, we will discuss the most relevant
consequences of lysosomal dysfunction for plaque development.
Lysosomal Iron Metabolism
It is consensual that atherogenesis begins with the oxidation
of LDL in the vascular wall, yet the molecular details of this
process are still the subject of debate (Steinbrecher et al., 1984;
Leake and Rankin, 1990; Steinberg, 2009). It is known that lipid
peroxidation requires the presence of transition metals such as
copper and iron. Both metals, due to their redox potential, can
catalyze the oxidation of polyunsaturated fatty acid moieties in
LDL particles. Atherosclerotic plaques present elevated levels of
iron and copper (Stadler et al., 2004), however, these metals exist
in tightly bound forms and are therefore not readily available
in the plasma and interstitial fluid (Dabbagh and Frei, 1995;
Ahmad and Leake, 2019; Wen et al., 2019). Lysosomes are crucial
for the regulation of the metabolism/homeostasis of iron and
copper (Polishchuk and Polishchuk, 2016; Kim et al., 2021). In
fact, the biggest pool of redox-active iron within cells is present
in these organelles (Petrat et al., 2001; Wen and Leake, 2007).
Lysosomal iron is thus a candidate for catalyzing the oxidation of
LDL in vivo. Indeed, the lysosomal acidic environment increases
the solubility of iron facilitating oxidation (Satchell and Leake,
2012). Furthermore, it has been demonstrated that LDL can
be oxidized within the lysosomes of macrophages (Lamb and
Leake, 1994; Ojo and Leake, 2018; Ahmad and Leake, 2019). In
contrast, when LDL are incubated with copper at acidic pH its
oxidation is delayed (Morgan and Leake, 1995), indicating that
LDL oxidation by copper within lysosomes is unlikely to occur.
Nonetheless, copper was shown to play an important role in
regulating the lipolysis of triglycerides (TG) via cAMP signaling
(Heffern et al., 2016). Therefore copper deficiency results in
elevated hepatic TG levels (Xiao et al., 2018), which have been
linked to atherosclerosis.
In recent years a novel link between lysosomal acidity and
iron availability has been established (Yambire et al., 2019; Weber
et al., 2020). Iron is delivered to lysosomes via receptor-mediated
endocytosis of transferrin (Tf) or autophagocytosis of ferritin and
organelles such as mitochondria (via mitophagy, the selective
elimination of non-functional and damaged mitochondria)
(Gammella et al., 2017). The ferritin and metalloproteins thus
delivered to lysosomes are degraded to form low molecular
weight iron (Kurz et al., 2007; Lv and Shang, 2018). Iron-loaded
Tf is endocytosed by binding the transferrin-receptor (TfR1). As
a consequence of vesicle acidification, iron is released from Tf
and transported to the cytoplasm, while Tf and TfR1 are recycled
back to the cell surface (Ullrich et al., 1996). Once iron dissociates
from Tf, the ferric iron must be reduced by STEAP proteins
before it is transported out of the endocytic compartment by
the Divalent metal transporter 1 (DMT1) (Touret et al., 2003).
Inhibition of the lysosomal v-ATPase impairs iron metabolism,
ultimately leading to loss of mitochondrial function and cell
death (Yambire et al., 2019). Additionally, iron uptake was
shown to be essential to maintain cell proliferation when
lysosomal pH is altered (Weber et al., 2020). The v-ATPase-iron-
mitochondria axis is thus fundamental for cellular homeostasis
and proliferation. Future research should elucidate whether
this axis plays a role in atherogenesis, given the noted altered
lysosomal pH and iron metabolism in atherosclerotic plaques.
In this regard, elevated levels of ferritin in atherosclerotic
arteries have been associated with myocardial infarction (Salonen
et al., 1992; You et al., 2003), while Tf levels show a negative
correlation with coronary heart disease by binding labile free iron
(Das De et al., 2015).
Inflammation
Lysosomes play a decisive role in cytokine release during
atherosclerosis progression (Gibson et al., 2018; Hassanpour
et al., 2019). Particularly, secretory lysosomes facilitate the release
and the degradation of cytokines that require non-conventional
secretion (Gibson et al., 2018). This “secretory” lysosome subset
can either promote or suppress inflammation, depending on
the stage of the inflammatory response. Another important
aspect to consider is the role played by lysosomes in the
activation of the NLRP3 inflammasome. NLRP3 inflammasome
activation results in the maturation and release of IL-1β, a
cytokine with a fundamental role in establishing and driving
the pathogenesis of atherosclerosis (Gibson et al., 2018). NLRP3
activation in macrophages requires two signals. The first
“priming” signal is NLRP3 transcription through NF-κB or
breast cancer 1 (BRCA1)–BRCA2-containing complex (BRCC)
3 activation, leading to the synthesis of biologically inactive
pro-IL-1β. The second signal can be delivered by a number of
different sources, including dysfunctional lysosomes (Tall and
Yvan-Charvet, 2015). This signal consists of NLRP3 activation
and apoptosis-associated speck-like protein containing CARD
(ASC) phosphorylation, which leads to the formation of the
cytosolic NLRP3 inflammasome complex. This multiprotein
complex is responsible for the synthesis of a mature form
of caspase-1, which in turn cleaves pro-IL-1β, producing the
mature and bioactive cytokine (Figure 1E). Regarding IL-1β
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release, several mechanisms have been described, including
exocytosis by secretory lysosomes, exosomes, and microvesicle
shedding (Gibson et al., 2018). As mentioned before, cholesterol
oxidation products and CC affect the permeability of the
lysosomal membrane, causing the leakage of hydrolases into
the cytosol (Li et al., 1998a; Yuan et al., 2000; Emanuel
et al., 2014). The release of cysteine proteases cathepsin B and
L from these dysfunctional lysosomes can, at least partially,
provide the second signal necessary for NLRP3 activation
(Duewell et al., 2010). Both oxLDL and exogenous CC can
induce IL-1β release in macrophages, even in the absence
of other stimuli, demonstrating they provide both signals
required for NLRP3 activation (Duewell et al., 2010; Sheedy
et al., 2013). Additionally, NLRP3 inflammasome activation
by lysosomal destabilization also requires particulate matter-
mediated K+ efflux, although the exact mechanism linking these
two events is unclear (Muñoz-Planillo et al., 2013; He et al.,
2016). The molecular details of NLRP3 activation fall outside
the scope of this review and have been discussed elsewhere
(Karasawa and Takahashi, 2017; Gibson et al., 2018; Jin and Fu,
2019).
mTOR Signaling
mTOR is a constitutively active kinase found in two different
multiprotein complexes, mTORC1 and mTORC2 kinase
complexes. Lysosomes receive information from the extracellular
environment regarding the nutritional status of the cell
via a complex machinery referred to as lysosomal nutrient
sensing (LYNUS) (Napolitano and Ballabio, 2016). The
LYNUS machinery is present at the lysosomal surface and
generates a signaling response through mTORC1 (Zoncu
et al., 2011; Bar-Peled and Sabatini, 2012). Cholesterol is
among the nutrients sensed at the lysosomal membrane,
regulating cellular signaling as well as cell proliferation and
autophagy via the activation of mTORC1 (Castellano et al.,
2017; Meng et al., 2020; Figure 1C). In NPC disease (NPC1
and NPC2 deficiency), intralysosomal FC accumulation
due to defective export causes mTORC1 hyperactivation,
mitochondrial dysfunction and impaired mitophagy, underlying
the pathognomonic neurodegeneration (Davis et al., 2021).
Given that mitophagy is a protective mechanism against oxLDL-
mediated apoptosis of VSMCs (Swiader et al., 2016; Docherty
et al., 2018; Yang Y. et al., 2020), safeguarding plaque stability,
it would be of interest to explore the contribution of aberrant
cholesterol-mTORC1 signaling to organelle pathogenesis in
atherosclerosis.
In the case of macrophages, the mTOR pathway is not
only a key sensor of nutrient status, but also the coordinator
of metabolic and inflammatory signals determining activation
of these cells (Vergadi et al., 2017). Macrophages can thus
obtain an array of activation phenotypes, depending on
the signals. These stages of macrophage activation can be
broadly described as M1 and M2 polarization, depending
on the activation stimulus. The metabolic and inflammatory
signals converge to the PI3K/Akt/mTOR signaling pathway,
that regulates the response of macrophages by modulating
their activation phenotype (Vergadi et al., 2017). In particular,
mTORC1 hyperactivation impairs the ability of macrophages to
respond appropriately to polarizing stimuli by downregulating
the downstream activity of Akt (protein kinase B) (Byles
et al., 2013). In agreement, Razani and colleagues report that
mTORC1-deficient mice present reduced atherosclerosis and
plaque complexity (Zhang X. et al., 2019). They, however,
suggest a divergent role for mTORC2 signaling in atherosclerosis,
seeing as macrophage-specific mTORC2-deficient mice present
larger and more complex lesions (Zhang X. et al., 2019). These
differences may be explained by distinct impacts in macrophage
polarization. Signaling by mTORC2 appears to inhibit the
FoXO1 transcription factor, causing a suppression of the pro-
inflammatory phenotype, particularly inflammasome activation
and IL-1β levels (Su et al., 2009; Zhang X. et al., 2019). Curiously,
they also report that deletion of macrophage mTOR, ablating
both mTOR-dependent pathways, leads to residual alterations
in atherosclerosis, reflecting the opposing effects of these two
signaling pathways (Zhang X. et al., 2019).
Exocytosis
Conventional lysosomes are not secretory organelles.
Nonetheless there is strong evidence supporting the existence
of an “unconventional” secretory pathway involving lysosomes,
known as lysosomal exocytosis (Ballabio, 2016). This process
implies the secretion of lysosomal contents upon fusion with
the plasma membrane, an important mechanism of cellular
clearance, necessary to maintain cell fitness (Buratta et al., 2020).
This “unconventional” secretion involves a small fraction of
lysosomes localized in the vicinity of the plasma membrane. In
the first step of lysosomal exocytosis, the peripheral lysosomes
are transported to the close proximity of the cell surface via
microtubules, kinesin motors and small G proteins in a Ca2+-
independent manner (Jaiswal et al., 2002; Encarnação et al.,
2016). The docking and fusion of peripheral lysosomes with
the plasma membrane is controlled by TFEB, in a process that
requires the lysosomal calcium channel TRPML1 (transient
receptor potential mucolipin 1) (Medina et al., 2011) and the
calcium-sensor synaptotagmin (Reddy et al., 2001). Several
lines of evidence suggest that increased lysosomal exocytosis
may exacerbate atherogenesis by releasing to the extracellular
space undigested material that is later engulfed by phagocyting
macrophages (Gibson et al., 2018; Figure 1E). Supporting this
claim, increased levels of multiple lysosomal hydrolases have
been detected in atherosclerotic plaques (Hakala et al., 2003;
Cheng et al., 2011). Among these enzymes with increased
extracellular activity can be counted LAL, as well as the proteases
cathepsin B, L, K, S, and D (Sukhova et al., 1998; Hakala
et al., 2003; Liu et al., 2006a,b; Platt et al., 2007; Li et al., 2009;
Cheng et al., 2011). Extracellular LAL and cathepsin D activity
contribute to the hydrolytic modification of LDL, promoting
its uptake by macrophages (and VSMCs) and subsequent foam
cell formation (Hakala et al., 2003; Zhao and Herrington, 2016).
Cathepsins B and S, on the other hand, have been shown to
degrade the ECM and thereby increase plaque vulnerability (De
Nooijer et al., 2009; Zhao and Herrington, 2016; Figure 1E).
Increased levels of these hydrolases are not restricted to the
arterial extracellular space, since elevated cathepsin B, S, and D
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levels have been detected in the circulation of patients suffering
from CVDs. The circulation levels of the hydrolases appear to
be related with increased risk of cardiovascular events (Naseem
et al., 2005; Liu et al., 2006a; Wuopio et al., 2018).
Autophagy
Autophagy is a highly evolutionarily conserved process with
crucial roles in the degradation and recycling of long-lived
or damaged intracellular material, including accumulated lipids
(Martinet and De Meyer, 2009; Yang et al., 2018). Autophagy
starts with the de novo formation of double-membrane–
bound vesicles that elongate and sequester the cytosolic
components, forming autophagosomes. These vesicles then
fuse with hydrolase-rich lysosomes, forming autolysosomes,
the vesicles in which proteolysis of substrates takes place.
Nutrient deprivation triggers non-selective autophagy involving
random uptake of cytoplasm portions, while selective autophagy
specifically removes certain components, such as protein
aggregates and damaged or superfluous organelles (Gatica et al.,
2018). Cellular components targeted for selective autophagy are
first recognized by “autophagy receptors,” which then interact
with adaptor proteins that recruit the core autophagy-related
(ATG) proteins, initiating autophagosome formation.
As mentioned above, the selective autophagic degradation
of LDs—lipophagy—in plaque macrophages is crucial for
maintaining cholesterol homeostasis in these cells, by delivering
CE for lysosome-mediated cholesterol efflux (Singh et al., 2009).
Several groups have reported an impairment of autophagy
in plaque macrophages as a consequence of (modified) lipid-
induced lysosomal stress and dysfunction (Yancey and Jerome,
1998; Duewell et al., 2010; Peden et al., 2011; Wild et al.,
2011; Razani et al., 2012; Sheedy et al., 2013). Besides
impaired lipophagy, other potential mechanisms underlying this
observation may include hyperactivation of the inflammasome
and IL-1β signaling, defective efferocytosis, and increased cell
death due to accumulation of cytotoxic protein aggregates (Sergin
et al., 2017; Evans et al., 2018). Additionally, a recent publication
demonstrated that SR class B type I (SR-BI) is necessary to
maintain macrophage autophagy in atherosclerosis through a
mechanism involving TFEB expression and VPS34/Beclin-1
recruitment (Tao et al., 2021).
Researchers have corroborated autophagy’s vital role in
preventing plaque formation, by demonstrating that disruption
of this mechanism in mouse macrophages (by deletion of the
essential autophagy protein ATG5) leads to marked increases
in atherosclerosis (Ouimet et al., 2011; Liao et al., 2012; Razani
et al., 2012). The group of Razani demonstrated that the
acceleration of plaque formation under these conditions is
due to an exacerbation of CC accumulation and subsequent
hyperactivation of the NLRP3 inflammasome and selective IL-
1β secretion (Sergin et al., 2017). Vindicating these studies, they
have also reported a general decrease in autophagy in human
and murine advanced atherosclerotic lesions (Sergin et al., 2017),
featuring the presence of inclusion bodies with p62/SQSTM1,
a chaperone for selective autophagy of cargo such as protein
aggregates (Razani et al., 2012; Sergin et al., 2016). These
inclusion bodies were shown to stem from plaque macrophages
with impaired lysosomal degradative capacity, and consequently
progressive autophagy dysfunction. Based on this cumulative
evidence, the group proposes the pharmacological modulation
of the autophagy-lysosomal biogenesis in macrophages as
a promising therapeutic avenue for atherosclerosis (see the
“Boosting Lysosome Biogenesis” section) (Sergin et al., 2017;
Evans et al., 2018).
In ECs, oxLDL and other atherogenic insults stimulate
autophagy to promote cell survival (Torisu et al., 2016). This
pro-survival mechanism is countered, however, by low/disturbed
shear stress, which impairs autophagy, promoting apoptosis and
senescence (Vion et al., 2017). Additionally, this protective effect
can also be attenuated by prolonged exposure to oxLDL, which
eventually inhibits autophagy, especially lipophagy (Mollace
et al., 2015; Zhang et al., 2020). Similarly, in VSMCs low
concentrations of oxLDL or its isolated components can also
induce autophagy (Ding et al., 2013; He et al., 2013), while
higher concentrations cause a drop in autophagy markers (Ding
et al., 2013). Grootaert et al. (2018) advocate that autophagy
coordinates a “fight (autophagy), adapt (senescence) or die
(apoptosis/necrosis)” mechanism in plaque VSMCs. According
to this model, VSMCs initially “fight” the stressful insults posed
by oxidized lipids, by boosting autophagy to promote their
removal (Hill et al., 2008; Ding et al., 2013). In this manner,
functional autophagy promotes plaque stability by modulating a
“phenotypic switch” in VSMCs from a contractile to a synthetic
phenotype (essential for ECM production) and inhibits cell death
(Salabei and Hill, 2013). However, when the cells’ “fighting”
resources are exhausted, they initiate an “adaptation” response
by undergoing proliferative arrest, with an associated increase
in senescence markers and eventually cell death, contributing to
plaque instability (Grootaert et al., 2015, 2018). We refer to two
excellent reviews for more details on the role of autophagy in
atherosclerosis (Evans et al., 2017; Grootaert et al., 2018). For
an overview of the relationship between autophagy-lysosomal
homeostasis and cellular senescence in atherosclerosis please
refer to our recent review (Machado-Oliveira et al., 2020).
Efferocytosis
Efferocytosis is a multistep process of engulfment of dead cells
by phagocytes that allows multicellular organisms to recycle
cellular components (Boada-Romero et al., 2020). The removal
of cellular corpses is important in both homeostasis and
disease. In advanced atherosclerosis, the death of macrophages
coupled with defective phagocytic clearance of foam cells,
promotes secondary necrosis, plaque expansion and rupture,
ultimately leading to acute coronary syndromes and stroke
(Poon et al., 2014; Boada-Romero et al., 2020). Monocyte-
derived macrophages are initially recruited into the developing
lesions by “find-me” chemotactic factors, such as chemokines
and lipids, secreted by dying cells (Yurdagul et al., 2018). At
this stage, macrophages display rapid and efficient efferocytosis,
effectively preventing the leakage of immunogenic peptides and
lipid contents from the apoptotic cells (Nagata et al., 2010;
Figure 1C). This restricts plaque progression by tempering post-
apoptotic necrosis and inflammation (Henson et al., 2001).
Engulfment of apoptotic cells by macrophages is made possible
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by an array of receptors that bind, directly or indirectly, to
“eat-me” signals displayed on the surface of the dying cells.
Live cells, in turn, are protected by the presence of “don’t
eat-me” signals on their surface (Yurdagul et al., 2018). Upon
recognition, the internalization of apoptotic cells results in the
formation of the so-called phagocytic cup, which then proceeds
with the retraction of the phagosome into the cell (Yurdagul
et al., 2018). After this step, the phagosome can follow one
of two routes, both heavily reliant on the lysosome-autophagy
axis. On the canonical route, phagosome maturation is mediated
through the activity of VPS34, phosphatidylinositol-3-phosphate
(PI3P), Rab proteins and other molecular traffic machinery
(Vieira et al., 2001; Flannagan et al., 2012). The fusion of the
late phagosome with lysosomes allows lysosomal hydrolases
to degrade the phagocytic cargo. Maturation of the phagocyte
is accompanied by increasing acidification in the lumen,
mediated by the v-ATPase (Martinez, 2017). Alternatively, the
phagosome can be modified to either facilitate or impair its
maturation. One such modification occurs during LC3-associated
phagocytosis (LAP), the second possible route, characterized by
the recruitment of LC3 to the phagosomal membrane (Martinez
et al., 2011; Santarino et al., 2017). This process is carried
out by a subset of proteins required for canonical autophagy
(ATG proteins) in combination with unique LAP regulators
(Martinez et al., 2015). LAP promotes the rapid maturation
of the phagosome, and lysosomal fusion. After degradation of
the apoptotic cells in phagolysosomes, macrophages become
overloaded with macromolecular constituents and need therefore
to either consume or efflux this cargo (A-Gonzalez et al., 2009;
Martinez, 2017).
As discussed earlier, autophagy, if not excessive, protects
macrophages against cell death. This is illustrated by the
fact that blocking autophagy worsens the recognition and
clearance of dead cells by efferocytes and promotes plaque
necrosis (Liao et al., 2012). Presently it is unclear why
efferocytosis fails in advanced atherosclerosis. Most studies
propose a dysregulation of “eat-me” and “don’t eat-me”
signals (Kojima et al., 2016; Cai et al., 2017). However, we
and others (Sergin et al., 2015) suggest a central role for
lysosomal dysfunction in this process. Although a direct link
between progressive lysosomal dysfunction and compromised
efferocytosis has not been investigated, impaired lysosomal
acidification and reduced hydrolase activity can be postulated
to adversely impact the ability of macrophages to handle
exogenous phagocytic cargo. Substantiating this view, studies
have proved the existence of a link between lysosomal storage
and impaired phagocytosis (Berg et al., 2016). Berg et al. (2016)
show that impaired lysosomal protease activity and consequent
accumulation of undigested material in macrophages, disrupt
the endocytic recycling and impair migration to, and thus
engulfment of, dying cells. In advanced plaques, unengulfed
apoptotic macrophages also start to accumulate and undergo
secondary necrosis. Another recent publication links the
inhibition of LAL with defective oxysterol production, which
in turn causes inflammasome activation, decreased cholesterol
efflux and impaired apoptotic cell clearance by macrophages
(Viaud et al., 2018).
TREATING ATHEROSCLEROSIS BY
TARGETING LYSOSOMES—THE
LESSONS TO BE LEARNED FROM LSDs
Scientists in the LSD field have been developing strategies to
circumvent the defects in lysosomal function associated with the
pathologies. These pharmacological and genetic strategies may
aim to directly correct the protein defect, to ameliorate pernicious
secondary effects or to provide a general boost in lysosome
function (Platt, 2018; Marques and Saftig, 2019). Despite recent
positive outcomes in clinical trials with therapeutics for the
treatment of atherosclerosis, namely those based on monoclonal
antibodies against IL-1β and PCSK9 (Ridker et al., 2017; Sabatine
et al., 2017), this disease remains the leading cause of death
worldwide. Targeting lysosomal dysfunction by making use of the
numerous tools developed by the LSD field may have a positive
impact on this ongoing search for improved therapeutics against
atherosclerosis. The studies discussed in this section are listed in
Supplementary Table 1.
LAL Supplementation
There is currently no curative treatment for LSDs. Although
gene therapy has made significant strides toward this goal
in the last years, the standard of care for most LSDs
(particularly the non-neuronopathic forms) is still enzyme
replacement therapy (ERT). ERT consists in the supplementation
with exogenous recombinantly produced lysosomal hydrolases
delivered intravenously (and more recently also intracranially)
(Platt, 2018; Schulz et al., 2018). ERT with recombinant LAL
(sebelipase alfa) is the standard therapy for Wolman disease
(LAL deficiency) and CESD since 2015 (Burton et al., 2015;
Wilson et al., 2018). LAL plays a crucial role in the hydrolysis
of lipoprotein-derived CE and TG during atherogenesis. As
already mentioned, LAL inhibition in macrophages decreases
the export of cholesterol via ABCA1 and impairs oxysterol
production and the efferocytosis of dead cells (Viaud et al.,
2018). Additionally, the gene encoding for LAL (LIPA) was
identified as a susceptibility gene for coronary artery disease
by several genome-wide association studies (Peden et al., 2011;
Wild et al., 2011). Given the central role of LAL in the
etiology of atherosclerosis, scientists have hypothesized that
supplementation with recombinant enzyme might also represent
a valid strategy to halt disease progression (Du and Grabowski,
2004; Dubland and Francis, 2015; Figure 2). LAL augmentation
was able to decrease atherosclerosis in a murine model (LDLR
knock-out mice) (Du et al., 2004) and the use of recombinant LAL
for the treatment of atherosclerosis continues to be investigated
(Grabowski and Du, n.d.). On the downside, ERT strategies
present substantial limitations regarding the elevated production
costs of recombinant enzymes, adverse immunological reactions
and the invasiveness of the delivery methods (Marques and
Saftig, 2019). There is also a knowledge gap concerning the
effects of systemic delivery of a recombinant hydrolase to
individuals not carrying a genetic deficiency. Nanotechnology
could prove a valuable asset for overcoming these limitations,
by allowing local and controlled delivery of the therapeutic
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FIGURE 2 | Therapeutics for atherosclerosis targeting lysosomal dysfunction.
Cyclodextrin (1) releases the FC sequestered inside lysosomes. ERT (2) is
based on the delivery of recombinant LAL that is taken up by
mannose-6-phosphate receptors (M6PR) and directed to the lysosomes. In
the acidic lumen of lysosomes LAL is released from the M6PR and catalyzes
the hydrolysis of accumulated CE. Cathepsin (CTS) inhibitors (3) may be
beneficial to plaque stability by preventing the degradation of the ECM, and by
decreasing the aggregation of LDL, which hampers its uptake by
non-regulated SRs. Both mTOR inhibitors (4) and trehalose (5) drive lysosome
biogenesis by stimulating the translocation of TFEB to the nucleus where it
drives the transcription of lysosomal genes. SRT (6) is based on the inhibition
of the (glucosylceramide) synthase responsible for the production of
glycosphingolipids (GSLs) that would otherwise accumulate inside lysosomes.
All these strategies, with the exception of (3), have the potential to decrease
the accumulation of lysosomal substrates and thereby restore membrane
integrity, preventing cathepsin release and NRLP3 inflammasome activation
(IL-1β production and release). This has only been experimentally
demonstrated in the case of trehalose treatment. Some images in this figure
were adapted with permission from Servier Medical Art, licensed under a
Creative Common Attribution 3.0 Generic License (http://smart.servier.com/).
enzyme (Del Grosso et al., 2019; Kim et al., 2020a). Nonetheless,
even under these circumstances, augmenting the hydrolysis
of lipoprotein CE may increase lysosomal membrane FC and
thereby exacerbate lysosomal dysfunction. Further studies are
thus warranted to firmly establish the safety of this approach.
Substrate Reduction Therapy
Substrate reduction therapy (SRT) is an alternative therapeutic
approach often employed in LSDs whenever treatment by
ERT is not feasible. Approved SRT strategies involve the
pharmacological inhibition of the synthesis of glycosphingolipids
(GSLs), a class of membrane lipids that undergo lysosomal
breakdown and that is often a primary or secondary storage
product of LSDs (Aerts et al., 2017; Platt, 2018). Multiple GSLs,
such as the building block ceramide, are bioactive lipids, and
impairment of their degradation may thus have considerable
consequences for pathological processes. Similarly to LSDs,
accumulation of GSLs has been demonstrated in human and
murine atherosclerotic lesions (Garner et al., 2002), as well as in
the circulation of atherosclerosis patients (Dawson et al., 1976;
Chatterjee et al., 1997). The accumulation of these metabolites
is most likely a consequence of the general impairment of
lysosomal degradative capacity. Many of these storage lipids have
been associated with pro-atherogenic properties. For example,
ceramide increases lipoprotein aggregation (Park et al., 2006)
and lactosylceramide promotes cholesterol accumulation (Gong
et al., 2004). GSLs in general have been associated with
inflammation and plaque instability (Park et al., 2006; Edsfeldt
et al., 2016). Accordingly, several groups have demonstrated
that pharmacological inhibition of GSL synthesis, through
the inhibition of the enzyme glucosylceramide synthase (the
enzyme that catalyzes the synthesis of the precursor of complex
GSLs) with different drugs, ameliorates atherosclerosis in mouse
models (Bietrix et al., 2010; Chatterjee et al., 2014; Mishra
et al., 2015; Yu et al., 2019; Figure 2). The use of the serine
palmitoyltransferase inhibitor myriocin, blocking the first step
in sphingolipid biosynthesis, also improved atherosclerosis (Park
et al., 2004; Hojjati et al., 2005). One study, however, found
no atheroprotective effects concomitant to the reduction of
GSLs in atherosclerosis-prone ApoE-deficient mice (Glaros et al.,
2008). Further studies are thus required in order to confirm the
involvement of GSLs in the atherogenic cascade as well as their
potential as therapeutic targets for atherosclerosis.
Cyclodextrins
The events taking place locally in the arterial wall share a lot
of similarities with the events occurring systemically in NPC
patients and animal models. In NPC disease, the macrophages are
also particularly affected by the intralysosomal FC accumulation
due to defective export machinery. The NPC1 protein has been
shown to protect LDLR-deficient mice against the development
of atherosclerosis through the regulation of LXR-dependent
cholesterol efflux and mitigation of cholesterol-induced oxidative
stress in macrophages (Welch et al., 2007; Zhang et al., 2008).
It is therefore not surprising that therapies with demonstrated
potential to treat NPC disease are also being investigated in the
context of atherosclerosis, the clinical use of cyclodextrins being a
prime example. Cyclodextrin (2-hydroxypropyl-β-cyclodextrin)
was initially devised as a vector to deliver the neurosteroid
allopregnanolone to an NPC mouse model. However, pre-
clinical trials revealed the positive effects in animal longevity
to be caused by the cyclodextrin-mediated release of the
cholesterol sequestered in the late endosome-lysosome pool into
the cytosolic pool (Griffin et al., 2004; Davidson et al., 2009;
Figure 1E). While clinical trials for the treatment of NPC
with cyclodextrin are still ongoing (Ory et al., 2017; Hastings
et al., 2019), they have in the meantime triggered the interest
of the CVD research field. Pre-clinical studies have shown
that cyclodextrin can promote atherosclerosis regression in
ApoE−/− mice by reprogramming macrophages (i.e., increased
oxysterol production and consequent LXR-mediated increase of
cholesterol efflux) (Zimmer et al., 2016). Additionally, VSMCs
and ECs treated with different cyclodextrins showed reduced
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cellular cholesterol content and modulated expression of ABC
transporters involved in reverse cholesterol transport (Coisne
et al., 2016). Despite the potential health benefits, the use of
cyclodextrin has been linked to significant hearing loss in animal
models and humans (Crumling et al., 2017). New formulations of
cyclodextrin continue to be investigated that could assist in the
mitigation of this pernicious side-effect (Kim et al., 2020b,c).
mTOR Inhibitors
Recent studies have demonstrated that mTOR inhibitors
have unique anti-atherosclerotic effects, including induction
of autophagy, depletion of plaque macrophages, activation of
cholesterol efflux and inhibition of pro-inflammatory signaling
(Castro et al., 2004; Pakala et al., 2005; Mueller et al., 2008;
Kurdi et al., 2016; Zhang K. S. et al., 2019; Figure 1E).
However, a major shortcoming of this approach is the associated
dyslipidemia (Holdaas et al., 2015). Several strategies, such as
combination therapy with statins and metformin, have been
suggested to oppose adverse side-effects caused by mTOR
inhibitors. Statins and metformin are two drugs widely used
to reduce cardiovascular risk that are also known to inhibit
mTORC1 indirectly via 5′ adenosine monophosphate-activated
protein kinase (AMPK) activation (Sun et al., 2006; Seneviratne
et al., 2020). These approved drugs may thus be ideal candidates
for exploiting the full potential of mTORC1 inhibition in the
treatment of atherosclerosis (Martinet et al., 2014; Kurdi et al.,
2017). This strategy may also potentiate the correct polarization
of macrophages via the inhibition of the PI3K/Akt/mTOR
signaling pathway (Sun et al., 2018).
Cathepsin Modulators
Lysosomal cathepsins, particularly when present in the
extracellular milieu, have been implicated in the etiology of
CVDs (Cheng et al., 2011; Liu et al., 2018). The extra-lysosomal
activity of these proteases mediates several atherogenic processes,
such as immune and vascular cell recruitment, angiogenesis,
oxLDL degradation, ECM remodeling and cell death (Cheng
et al., 2011; Liu et al., 2018). The importance of these proteases
for the atherogenic cascade has been demonstrated by numerous
studies evidencing that their genetic or pharmacological ablation
(namely of cathepsin C, K, L, and S) hinders atherosclerotic
plaque formation (Sukhova et al., 2003; Bengtsson et al., 2005;
Lutgens et al., 2006; Kitamoto et al., 2007; Figueiredo et al., 2015;
Herías et al., 2015). Altogether these studies suggest that,
besides being potential biomarkers for CVDs, cathepsin
proteases may also represent promising therapeutic targets to
delay plaque progression (Figure 2). Given the crucial role
of these enzymes in cell homeostasis, therapeutic approaches
targeting them must find a delicate balance between inhibition
of excessive extracellular activity and maintenance of their
physiological functions.
Boosting Lysosome Biogenesis
TFEB is the master regulator of autophagy and lysosome
biogenesis (Sardiello et al., 2009). Consequently, overexpression
of this transcription factor increases the number of lysosomes
and enhances lysosomal catabolic activity. This feature could be
crucial in a pathophysiological context in which old lysosomes
become dysfunctional and undegraded cargo accumulates
(Sardiello et al., 2009). Scientists in the field of atherosclerosis
were motivated by these observations to try to ameliorate
atherosclerosis and vascular aging through the pharmacological
and genetic enhancing of the macrophage autophagy-lysosomal
system (LaRocca et al., 2013; Emanuel et al., 2014). In vitro studies
have demonstrated that increasing lysosomal biogenesis through
TFEB overexpression can rescue the lipid-induced lysosomal
dysfunction, reduce inflammasome activation and decrease
atherosclerosis progression (Emanuel et al., 2014). These findings
were confirmed by in vivo studies reporting the reduction of
atherosclerosis in murine models through the overexpression
of macrophage TFEB (Sergin et al., 2017). Boosting lysosome
biogenesis in mouse macrophages reversed the observed
defects in autophagy by enhancing their degradative capacity,
stimulating the selective degradation of p62-enriched protein
aggregates (aggrephagy) and halting macrophage apoptosis and
pro-inflammatory IL-1β levels (Sergin et al., 2017; Evans et al.,
2018). Clearance of lipid-laden lysosomes by exocytosis may also
represent a TFEB-dependent mechanism for the alleviation of
the autophagy-lysosomal system (Medina et al., 2011). Moreover,
boosting TFEB-mediated lysosome clearance was shown to be
beneficial to cardiac cells (Ma et al., 2012; Pan et al., 2017). In
atherosclerotic plaques, stimulating exocytosis may, however, not
be entirely beneficial, as it could contribute to the release of
partially degraded and oxidized lipoproteins to the extracellular
space, promoting atherogenesis.
Notably, the group of Razani has also demonstrated the
feasibility of employing the non-reducing natural disaccharide
trehalose as a means of pharmacologically boosting lysosome
biogenesis and recapitulating the atheroprotective effects of
TFEB overexpression (Sergin et al., 2017; Figure 2). Previous
studies by others had already shown that pharmacological
induction of autophagy with the polyamine spermidine could
reverse arterial aging (LaRocca et al., 2013). Trehalose is also a
potent inducer of autophagy, through yet unknown mechanisms,
and is able thereby to ameliorate various protein aggregation
neurodegenerative diseases (Tanaka et al., 2004; Sarkar et al.,
2007; Rodríguez-Navarro et al., 2010). Trehalose also induces the
translocation of the MiT/TFE family member TFE3, but not of
MITF (Sergin et al., 2017). TFE3 and TFEB regulate overlapping
sets of genes and their overexpression has similar effects (Martina
et al., 2014). These two transcription factors demonstrate a
cooperative and partially redundant effect and function as
master integrators of different stress pathways, controlling
the expression of key genes involved in the modulation of
the immune response, metabolism, mitochondrial homeostasis,
and unfolded protein response (Martina et al., 2014; Pastore
et al., 2016; Martina and Puertollano, 2017). The individual
importance of each transcription factor for plaque cells under
pro-atherogenic conditions remains an open question.
A potential drawback of boosting MiT/TFE expression could
be the unwanted deregulation of cell proliferation control
(Marques and Saftig, 2019). Underlying this concern is the fact
that MiT/TFE proteins have demonstrated oncogenic features
in multiple malignancies, including melanoma and renal cell
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carcinoma (Haq and Fisher, 2011; Kauffman et al., 2014;
Perera et al., 2019). There are thus well-founded concerns
that excessive MiT/TFE activity could promote malignancy
development, namely through an hyperactivation of the WNT
pathway (Calcagnì et al., 2016). Future research must ascertain
the safety of these therapeutic strategies, perhaps by focusing on
local and transient ways of boosting lysosome biogenesis.
Alternative Regulators of Lysosome Biogenesis
TFEB-mediated induction of lysosome biogenesis does not
paint a complete picture of the intricate regulation of the
autophagy-lysosomal system. The activation of a pro-degradative
transcriptional program can involve other molecular players.
Among the transcription factors shown to modulate the
expression of lysosomal and autophagy genes can be counted the
FoxO transcription factors, the signal transducer and activator
of transcription 3 (STAT3) and c-MYC (Kreuzaler et al., 2011;
Shin et al., 2016; Yan et al., 2016; Martínez-Fábregas et al.,
2018; Annunziata et al., 2019). The unique feature of these
three transcription factors is that they have also been reported
to influence the development of atherosclerosis (Napoli et al.,
2002; Tsuchiya et al., 2012; Wang et al., 2016; Yang X. et al.,
2020). However, it remains unclear whether this involvement
is related to their role in the homeostasis of the lysosome-
autophagy axis.
CONCLUSION
Almost 50 years after its publication, the original observation
by De Duve, the scientific “father” of lysosomes, has been
vindicated. A large body of evidence has been produced
confirming the central role played by lysosomal dysfunction in
atherogenesis. Such studies have demonstrated that lysosomes
alone must process the lipoproteins trapped in the arterial
wall during atherosclerotic plaque development. While their
catalytic function in ECs, VSMCs and macrophages—the
main cell types of the arterial wall—remains intact in the
initial stages of plaque development, eventually the influx of
substrates surpasses the capacity of these small organelles. The
advent of extracellular and/or intracellular modifications in the
lipoproteins, throws a final wrench into the endolysosomal
compartment, halting its primary function as the degradative
compartment of the cell and, as a consequence, its secondary
(albeit crucial) functions.
Although significant progress has been made in the
understanding of the etiology and the consequences of lysosomal
dysfunction in arterial plaque cells, substantial questions remain.
Scientists are still to clarify, among other questions: exactly
where and how modifications in lipoproteins occur; which
components of oxLDL underlie its atherogenic properties; and
how the different transcription factors orchestrate the response
to a dysfunctional lysosomal compartment. Here we argue that, in
order to answer these questions, scientists in the field may benefit
from the knowledge gathered since the 1950’s by researchers
studying LSDs, monogenic inherited disorders affecting the
functioning of lysosomes. The advantages of the cooperation
between these domains of expertise are already evident. For
example, initial observations by scientists investigating LSDs
enabled researchers to study the key role of the transcription
factor TFEB, the master regulator of lysosome biogenesis, in
the development of atherosclerosis. Additionally, many markers
of autophagy-lysosomal dysfunction may also be employed as
(bio)markers for atherosclerosis prognosis (e.g., p62 aggregates,
extracellular LAL levels, circulating cathepsin levels, etc.). Finally,
this cooperation has already brought to light the fact that
therapeutic interventions aiming to compensate the individual
deficiencies in lysosomal proteins or to boost the autophagy-
lysosomal machinery as a whole, hold considerable potential for
the treatment of atherosclerosis. The knowledge thus gathered
may assist in the ongoing efforts to minimize the morbidity and
mortality associated to atherosclerosis.
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